Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage
暂无分享,去创建一个
S. Kische | T. Betts | B. Schmidt | D. Foley | H. Mudra | G. Nickenig | J. Bonnet | E. Teiger | I. Cruz-González | A. Vahanian | K. Stein | T. Gori | D. Gras | H. Sievert | E. Pokushalov | L. Boersma | T. Szili-Torok | D. Crossland | P. Mazzone | C. Tamburino | M. Spence | J. Thambo | P. Defaye | L. Boldt | T. Fiedler | A. Sukiennik | T. Schmitz | T. Wong | F. Brigadeau | H. Ince | F. Meincke | G. Molon | T. D. De Potter | R. Folkeringa | G. Senatore | A. Protopopov | M. Grygier | M. Bergmann | M. Busch | Elisa Vireca | Arif Al Nooryani | C. Wald | W. Tschishow | Faisal Al Smadi | Robin Molitoris | Y. Stevenhagen | Eduardo Infante Oliveira | E. Merkulov | M. Neef | A. Al Nooryani
[1] P. Garot,et al. Device-Related Thrombus After Left Atrial Appendage Closure , 2018, Interventional cardiology.
[2] V. Reddy,et al. Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes , 2018, Circulation.
[3] S. Connolly,et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source , 2018, The New England journal of medicine.
[4] Pascal Defaye,et al. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation. , 2018, Journal of the American College of Cardiology.
[5] D. Fitzmaurice,et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation , 2018, PloS one.
[6] Saibal Kar,et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. , 2017, Journal of the American College of Cardiology.
[7] Xavier Freixa,et al. Device‐associated thrombus formation after left atrial appendage occlusion: A systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet , 2017, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[8] S. Kische,et al. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[9] S. Kische,et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. , 2017, Heart rhythm.
[10] M. Rosenqvist,et al. Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[11] J. Nielsen-Kudsk,et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[12] Dhanunjaya R. Lakkireddy,et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[13] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[14] T. Betts,et al. EWOLUTION: Design of a registry to evaluate real‐world clinical outcomes in patients with AF and high stroke risk‐treated with the WATCHMAN left atrial appendage closure technology , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[15] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.
[16] P. Neužil,et al. Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation. , 2016, Journal of the American College of Cardiology.
[17] S. Kische,et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry , 2016, European heart journal.
[18] M. Price,et al. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. , 2015, JACC. Cardiovascular interventions.
[19] I. V. Van Gelder,et al. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial , 2015, Trials.
[20] K. Chun,et al. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. , 2013, Heart rhythm.
[21] Yan Sun,et al. 5-year survival and rehospitalization due to stroke recurrence among patients with hemorrhagic or ischemic strokes in Singapore , 2013, BMC Neurology.
[22] Mårten Rosenqvist,et al. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. , 2012, European heart journal.
[23] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[24] Jun Zhu,et al. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[25] Gregory Y H Lip,et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.
[26] P. Serruys,et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium , 2010, European heart journal.